HAEMONETICS CORP (HAE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-28. Amounts in USD.

Revenue Annual

0 500M 1B 1.5B FY11: 645.4M FY12: 676.7M FY12: 727.8M FY13: 892M FY14: 938.5M FY15: 910.4M FY18: 886.1M FY18: 903.9M FY19: 967.6M FY20: 988.5M FY22: 870.5M FY23: 993.2M FY24: 1.2B FY24: 1.3B FY25: 1.4B FY26: 1.3B FY12 FY13 FY15 FY18 FY20 FY23 FY24 FY26

Gross Profit Annual

0 300M 600M 900M FY09: 308.2M FY11: 337.5M FY12: 355.2M FY12: 369.2M FY13: 428.1M FY14: 468.4M FY15: 434.4M FY17: 405.9M FY18: 378.5M FY18: 411.9M FY19: 417.5M FY20: 484.5M FY22: 397.8M FY23: 505.5M FY24: 615.1M FY24: 691.5M FY25: 749M FY26: 787.6M FY11 FY12 FY14 FY17 FY18 FY20 FY23 FY24 FY26

Operating Income Annual

-80M 0 80M 160M 240M FY09: 85.6M FY11: 83.3M FY12: 110.5M FY12: 88.8M FY13: 56.4M FY14: 46.4M FY15: 40.5M FY17: -43.9M FY18: -19.4M FY18: 56.2M FY19: 83.5M FY20: 103.4M FY22: 89.7M FY23: 80.8M FY24: 156M FY24: 164.9M FY25: 221.8M FY26: 156.7M FY11 FY12 FY14 FY17 FY18 FY20 FY23 FY24 FY26

Net Income Annual

-60M 0 60M 120M 180M FY09: 59.3M FY11: 58.4M FY12: 80M FY12: 66.9M FY13: 38.8M FY14: 35.1M FY15: 16.9M FY17: -55.6M FY18: -26.3M FY18: 45.6M FY19: 55M FY20: 76.5M FY22: 79.5M FY23: 43.4M FY24: 115.4M FY24: 117.6M FY25: 167.7M FY26: 97.3M FY11 FY12 FY14 FY17 FY18 FY20 FY23 FY24 FY26

Cost of Revenue Annual

0 250M 500M 750M FY18: 507.6M FY18: 492M FY19: 550M FY20: 504M FY22: 472.6M FY23: 487.7M FY24: 553.6M FY24: 617.5M FY25: 611.9M FY26: 546.4M FY18 FY18 FY19 FY20 FY22 FY23 FY24 FY24 FY25 FY26

Operating Cash Flow Annual

0 100M 200M 300M FY09: 116.4M FY11: 130.7M FY12: 123.5M FY12: 115.3M FY13: 85.1M FY14: 139.5M FY15: 127.2M FY17: 121.9M FY18: 159.7M FY18: 220.3M FY19: 159.3M FY20: 158.2M FY22: 108.8M FY23: 172.3M FY24: 273.1M FY24: 181.8M FY25: 181.7M FY26: 293.2M FY11 FY12 FY14 FY17 FY18 FY20 FY23 FY24 FY26

Free Cash Flow Annual

0 90M 180M 270M FY09: 60M FY11: 74.4M FY12: 76.8M FY12: 62.1M FY13: 22.9M FY14: 65.9M FY15: 5M FY17: 19.5M FY18: 83.6M FY18: 145.6M FY19: 40.3M FY20: 109.5M FY22: 71.8M FY23: 75.8M FY24: 81.7M FY24: 143.6M FY25: 142.4M FY26: 260.4M FY11 FY12 FY14 FY17 FY18 FY20 FY23 FY24 FY26

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY09: 26.2M FY11: 26.1M FY12: 51.2M FY12: 51.6M FY13: 52.3M FY14: 52.4M FY15: 52.1M FY17: 50.9M FY18: 51.5M FY18: 53.5M FY19: 52.9M FY20: 51.8M FY22: 51.3M FY23: 51.4M FY24: 51.4M FY24: 51.4M FY25: 50.7M FY26: 47.4M FY11 FY12 FY14 FY17 FY18 FY20 FY23 FY24 FY26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 0.00 1.50 3.00 4.50 Q1 '11: 2.25 Q2 '11: 2.26 Q3 '11: 2.42 Q4 '11: 2.48 Q1 '12: 3.13 Q2 '12: 3.08 Q3 '12: 2.77 Q3 '12: 2.36 Q4 '12: 1.90 Q1 '13: 1.44 Q2 '13: 1.03 Q3 '13: 0.86 Q4 '13: 0.75 Q1 '14: 0.41 Q2 '14: 0.60 Q3 '14: 0.72 Q4 '14: 0.67 Q1 '15: 0.75 Q2 '15: 0.57 Q3 '15: 0.57 Q4 '15: 0.32 Q1 '16: 0.38 Q2 '16: 0.49 Q3 '16: -0.99 Q1 '17: -1.10 Q2 '17: -1.29 Q3 '17: -1.16 Q3 '17: 0.31 Q1 '18: -0.50 Q2 '18: 0.08 Q2 '18: 0.08 Q3 '18: -0.34 Q4 '18: 0.86 Q1 '19: 0.43 Q2 '19: 0.40 Q3 '19: 0.87 Q4 '19: 1.05 Q1 '20: 0.93 Q2 '20: 1.30 Q3 '20: 1.53 Q4 '20: 1.47 Q1 '21: 1.85 Q2 '21: 2.07 Q3 '21: 2.11 Q1 '22: 1.55 Q2 '22: 1.25 Q3 '22: 0.60 Q4 '22: 0.43 Q1 '23: 0.84 Q2 '23: 1.31 Q3 '23: 1.66 Q3 '23: 1.85 Q1 '24: 2.23 Q2 '24: 2.65 Q2 '24: 2.49 Q3 '24: 2.46 Q4 '24: 2.29 Q1 '25: 2.23 Q2 '25: 2.41 Q3 '25: 2.54 Q4 '25: 3.31 Q1 '26: 3.27 Q2 '26: 3.42 Q3 '26: 3.63 Q3 '12 Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q4 '22 Q3 '24 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.